| 词条 | CX157 |
| 释义 |
| verifiedrevid = 396516252 | IUPAC_name = 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiine 10,10-dioxide | image = CX157 structure.svg | tradename = | pregnancy_category = | legal_status = Uncontrolled | routes_of_administration = Oral | bioavailability = | metabolism = | elimination_half-life = | excretion = | CAS_number = | ATC_prefix = none | ATC_suffix = | PubChem = 18687754 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 13701383 | C = 14 | H = 8 | F = 4 | O = 4 | S = 1 | molecular_weight = 348.27 g/mol | smiles = FC(F)(F)COc2cc3Oc1cc(F)ccc1S(=O)(=O)c3cc2 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C14H8F4O4S/c15-8-1-3-12-10(5-8)22-11-6-9(21-7-14(16,17)18)2-4-13(11)23(12,19)20/h1-6H,7H2 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = PDIMOTRDGUQMNY-UHFFFAOYSA-N }}CX157 (proposed trade name TriRima, formerly Tyrima) is a selective and reversible inhibitor of MAO-A (RIMA).[1] As of 2007 it was in phase II clinical trials for the treatment of depression.[2] In 2013, it was discontinued for both depression and anxiety. References1. ^{{cite conference |vauthors=Fielding R, Mielach F, Free J, Pande A |title=Pharmacokinetics and oral bioavailability of CX157, a reversible selective MAO-A inhibitor, in primates |year=2007 |conference=2007 AAPS Annual Meeting & Exposition |url=http://www.aapsj.org/abstracts/AM_2007/AAPS2007-001233.PDF |accessdate=2009-06-14}} {{Monoamine metabolism modulators}}{{nervous-system-drug-stub}}2. ^{{ClinicalTrialsGov|NCT00739908}} 3 : Reversible inhibitors of MAO-A|Monoamine oxidase inhibitors|Abandoned drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。